We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Borderline Anemia May Carry Higher Risk Than Current Thresholds Suggest

By LabMedica International staff writers
Posted on 08 Sep 2026

Hemoglobin concentration is among the most frequently ordered blood tests in primary and hospital care. More...

In older adults, both high and low values have been linked to adverse outcomes, including cognitive decline, cardiovascular disease, hospitalization, and death. Although anemia is commonly defined by the World Health Organization (WHO) as hemoglobin below 12 g/dL in women and 13 g/dL in men, a new study shows that borderline low levels just above these thresholds are also associated with increased mortality.

University of Glasgow researchers conducted a prospective cohort analysis of nearly half a million UK Biobank participants followed for more than 10 years. The investigation assessed the relationship between baseline hemoglobin concentration and long-term mortality risk using multiple statistical approaches. The study, titled “Association between blood haemoglobin concentration and mortality by age and sex: a prospective cohort study,” was published in Annals of Internal Medicine.

The analysis demonstrated a U-shaped association between hemoglobin and mortality, with the greatest risk at both extremes. The lowest all-cause mortality risk occurred at hemoglobin concentrations 1 to 3 g/dL above current WHO anemia thresholds in both men and women. Notably, individuals with “borderline anemia,” defined as values just above the diagnostic cutoff, had a higher mortality risk than those with higher hemoglobin within the WHO-defined normal range.

Hemoglobin testing is routine across care settings, yet current anemia thresholds have remained largely unchanged for five decades. Although higher-than-normal hemoglobin levels, or polycythemia, are rare, affecting about 7 per 100,000 people in the UK, anemia is common and has been associated with cognitive, cardiovascular, and hospitalization risks in older adults. The researchers emphasize that the study shows association rather than causation and does not demonstrate that investigating or treating people just above current thresholds would improve outcomes. Instead, the findings point to areas for future research and add to broader debate over how well long-standing diagnostic cutoffs reflect current risk.

“The most important purpose of clinical diagnostic criteria is to inform the management of patients. Currently, many clinicians do not even recognise a person has anaemia until its moderately severe, for example less than 11 g/dL. Showing that borderline anaemia is associated with increased risk and a high prevalence of iron deficiency should encourage investigation and treatment of a broad range of patients with mild/borderline anaemia,” said Professor John Cleland, Professor of Cardiology and senior author of the study.

“The very large study population, long follow-up and consistency across several statistical approaches make this a robust association. However, this remains an observational study. The next question is whether low-normal haemoglobin can help identify treatable underlying conditions and improve patient care,” said Professor Paul Welsh, Professor of Molecular Epidemiology and Director of the Glasgow Biomarker Research Unit at the University of Glasgow.

Related Links
University of Glasgow


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
New
Nucleic Acid Purification Instrument
QIAsymphony Connect
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers from the Department of Chemistry at Aarhus University have developed and tested a new technology that can identify and measure the concentration of pharmaceuticals in under 10 minutes. Today, this process takes up to an hour. That is critical waiting time for patients suffering from a stroke. (Image Credit: Aarhus University)

Point-of-Care Blood Test Could Speed Treatment Decisions in Acute Stroke

Minutes can shape treatment decisions in emergency stroke care, particularly when physicians need to know whether a patient is taking anticoagulants before administering clot-dissolving therapy.... Read more

Microbiology

view channel
Image: The clearance also broadens QIAstat-Dx\'s infectious disease testing menu in the U.S., which already includes panels for respiratory and gastrointestinal infections, as well as meningitis and encephalitis (Photo courtesy of Qiagen)

One-Hour Molecular Panel Expands Bloodstream Infection Testing for Gram-Negative Pathogens

Bloodstream infections can progress rapidly and lead to sepsis, organ failure, and death. In the United States, about 1.7 million adults develop sepsis each year, and at least 350,000 die during hospitalization... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.